97187298 - S

Information

  • Trademark
  • 97187298
  • Serial Number
    97187298
  • Filing Date
    December 23, 2021
    3 years ago
  • Transaction Date
    April 12, 2024
    8 months ago
  • Status Date
    April 11, 2024
    9 months ago
  • Published for Opposition Date
    August 22, 2023
    a year ago
  • Location Date
    October 17, 2023
    a year ago
  • First Use Anywhere Date
    March 15, 2021
    3 years ago
  • First Use In Commerce Date
    March 15, 2021
    3 years ago
  • Status Code
    730
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    MACFARLANE, JAMES W
  • Attorney Docket Number
    S21802000100
    Attorney Name
    Christina M. Licursi
    Law Office Assigned Location Code
    L40
  • Owners
Mark Drawing Code
3000
Mark Identification
S
Case File Statements
  • DM0000: The mark consists of a stylized S in the shape of a swan's wing.
  • GS0051: Therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene inhibition therapy and/or RNA interference (RNAi), for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene augmentation therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapies using intrathecal administration, for the treatment of genetic diseases and disorders and neurological diseases and disorders; biologic preparations for use in the treatment of genetically based diseases and disorders; biologic preparations for medical purposes, namely, for gene therapy for treating genetic disorders; pharmaceutical preparations that modulate RNA expression for the treatment of neurological diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; gene therapy products, namely, gene delivery pharmaceuticals for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical preparations for gene therapy, gene inhibition and gene augmentation, for the treatment of genetic diseases and disorders and neurological diseases and disorders; viruses, viral vectors and viral constructs, all in the nature of pharmaceutical preparations, for the treatment of neurological diseases and disorders and genetic diseases and disorders; pharmaceutical preparations for gene therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, nucleic acid therapeutics for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, DNA and/or RNA therapeutics for the treatment of genetic disorders and neurological diseases and disorders
  • GS0421: Development of pharmaceutical preparations for use in gene therapy; genetic engineering and biotechnology research; research and development of new products in the field of gene therapeutics; scientific and medical research in the field of genetics, gene therapy and genetic engineering; laboratory research in the fields of genetics, gene therapy, drug development, biotechnology, microbiology and molecular biology; pharmaceutical drug discovery; scientific research in the field of gene therapy discovery; drug development and therapeutic drug development; genetic drug development and therapeutic drug development; biological research; biological drug development and scientific research in the field of biological development
Case File Event Statements
  • 4/12/2024 - 8 months ago
    24 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 4/11/2024 - 9 months ago
    23 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 4/11/2024 - 9 months ago
    22 - SOU EXTENSION 1 FILED Type: EXT1
  • 4/11/2024 - 9 months ago
    21 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 10/17/2023 - a year ago
    20 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 8/22/2023 - a year ago
    19 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 8/22/2023 - a year ago
    18 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 8/2/2023 - a year ago
    17 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 7/19/2023 - a year ago
    16 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 6/29/2023 - a year ago
    15 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 6/29/2023 - a year ago
    14 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 6/29/2023 - a year ago
    13 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR
  • 5/19/2023 - a year ago
    12 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 5/19/2023 - a year ago
    11 - FINAL REFUSAL E-MAILED Type: GNFR
  • 5/19/2023 - a year ago
    10 - FINAL REFUSAL WRITTEN Type: CNFR
  • 4/10/2023 - a year ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 4/10/2023 - a year ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/10/2023 - a year ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 10/12/2022 - 2 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 10/12/2022 - 2 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 10/12/2022 - 2 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 9/27/2022 - 2 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 1/15/2022 - 2 years ago
    2 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC
  • 1/14/2022 - 2 years ago
    1 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS